PRMT5 and neoplasm: Finally, while no specific co‐occurring gene alteration was associated with a significant impact on OS in patients treated with ivosidenib, CDKN2A/B and MTAP alterations correlated with a worse PFS, suggesting a potential role in resistance to IDH1 inhibition or even the potential to combine IDH1 inhibitors with MTA‐cooperative PRMT5 inhibitors in MTAP deleted tumours to synergistically target different metabolic vulnerabilities.